Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
orpathys save search
AmeriGuard Security Services, Inc. Awarded Prestigious Contract by U.S. Department of Veterans Affairs for Non-Emergency Medical Transportation in the greater Los Angeles metropolitan area
Published: 2024-03-25 (Crawled : 15:30) - prnewswire.com
AGSS | $0.21 656.1% 1.1K
|
n/a
|
| O: 0.0%
H: 9.36%
C: 2.42%
angeles contract security medical
OVHcloud Opens New Data Center and Invests $145 Million in the Toronto Area
Published: 2024-03-13 (Crawled : 13:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
million
Light Source Communications Secures Deal with Major Global Hyperscaler to Bring Dark Fiber Route to Phoenix Metro Area
Published: 2024-03-13 (Crawled : 12:30) - prnewswire.com
PRIM | $43.53 0.93% 0.0% 610K
|
Industrial Services
|
| O: -0.27%
H: 0.64%
C: -0.17%
light global communications deal
Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area
Published: 2024-03-05 (Crawled : 14:30) - biospace.com/
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.21%
H: 0.84%
C: 0.81%
ceo bay sciences
Toll Brothers Announces Beckham Place at Morningside Model Home Grand Opening in Atlanta Area
Published: 2024-02-29 (Crawled : 22:00) - globenewswire.com
TOL | $112.21 -0.84% 0.0% 1.2M
|
Consumer Durables
|
| O: -0.12%
H: 2.49%
C: 2.11%
home
HILCO REAL ESTATE ANNOUNCES TWO DEVELOPMENT SITES AVAILABLE THROUGH BANKRUPTCY SALES IN THE GREATER NYC AREA
Published: 2024-02-20 (Crawled : 19:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
sales
Latham & Watkins Adds Prominent Emerging Companies & Growth Partners in Bay Area
Published: 2024-02-20 (Crawled : 18:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
bay companies growth
AMERANT BANK OPENS FIRST BANKING CENTER IN THE GREATER TAMPA AREA
Published: 2024-02-01 (Crawled : 20:00) - globenewswire.com
FRBA | $12.66 4.46% 4.27% 57K
|
Finance
|
| O: -1.47%
H: 1.8%
C: 0.37%
AMTB | $22.18 4.18% 0.0% 100K
|
Finance
|
| O: -2.69%
H: 2.9%
C: 2.03%
first
Monarch Truck Center to Host Ride and Drive of REE’s P7-C for Canteen, Stanford University, City of San Jose and Other Large Fleet Customers in the Bay Area
Published: 2024-01-25 (Crawled : 11:00) - globenewswire.com
REE | $3.685 -9.68% -10.72% 44K
|
|
| O: 1.64%
H: 0.0%
C: -3.95%
fleet bay city truck
La Rosa Opens Office in the Tampa Bay Area
Published: 2024-01-18 (Crawled : 14:00) - globenewswire.com
LRHC | News | $1.75 9.6% 47K
|
n/a
|
| O: 0.0%
H: 6.56%
C: 0.0%
bay rosa
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
Published: 2023-01-18 (Crawled : 15:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 1.32%
H: 4.49%
C: 1.01%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.36%
H: 0.33%
C: -1.13%
orpathys drug agreement china
HUTCHMED Receives a US$15 million Milestone from AstraZeneca for Initiating Start-up Activities for a Global Phase III Study of ORPATHYS® in Lung Cancer
Published: 2022-03-07 (Crawled : 05:00) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 2.76%
H: 0.0%
C: -1.8%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -10.68%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
orpathys star lung cancer one cancer milestone
HUTCHMED and AstraZeneca Initiate SACHI Phase III Trial of ORPATHYS® and TAGRISSO® Combination in Certain Lung Cancer Patients in China After Progression on EGFR Inhibitor Therapy
Published: 2021-11-24 (Crawled : 01:00) - globenewswire.com
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: -0.02%
H: 1.33%
C: 1.33%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -4.39%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
orpathys lung cancer china therapy cancer trial
HUTCHMED and AstraZeneca Initiate SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
Published: 2021-09-08 (Crawled : 11:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -2.29%
H: 1.34%
C: 1.29%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.85%
H: 0.17%
C: -0.42%
lung cancer china therapy cancer trial
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
Published: 2021-07-27 (Crawled : 01:00) - chi-med.com
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.58%
H: 0.0%
C: -0.4%
cancer trial
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
Published: 2021-07-28 (Crawled : 01:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 6.45%
H: 7.99%
C: 7.76%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.75%
H: 0.7%
C: -0.39%
cancer trial
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
Published: 2021-07-13 (Crawled : 07:00) - globenewswire.com
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: -0.45%
H: 2.92%
C: 2.12%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.68%
H: 0.94%
C: 0.87%
china milestone commercialization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.